Results from Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint in People with Type 1 and Type 2 Diabetes

Both studies also showed greater reductions in glucose excursions after mealtime INDIANAPOLIS, Oct. 2, 2018 -- (Healthcare Sales & Marketing Network) -- Readouts from two phase 3 clinical trials demonstrated that Eli Lilly and Company's (NYSE: LLY) Ult... Biopharmaceuticals, Endocrinology Eli Lilly, Ultra Rapid Lispro, diabetes
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news